SPECIAL REPORT

Click here to complete the quick poll on DMT preferences.
Submit your responses anonymously to be able to view the aggregate results of the poll.

Patient satisfaction with high-efficacy therapies
Switching therapies
Real-world impact on PIRA

Over 12,000 MS patients in Canada have been treated with ofatumumab, an anti-CD20 monoclonal antibody administered by self-injection, since it was authorized for use five years ago. A Canadian study has now examined patient acceptance of treatment in an analysis of patient support program (PSP) data (Selchen et al. Mult Scler Relat Disord 2026:107:106976). A total of 5436 of 6377 patients in the database met inclusion criteria. Treatment persistence was 96.94% at 12 months, 95.02% at 24 months and 92.26% at 36 months. The most common reasons for treatment discontinuation were side effects (0.9%), conception/pregnancy (0.5%) and patient request (0.5%). Read More

Anti-CD20 therapies for multiple sclerosis have come to dominate the therapeutic (and publishing) landscape. Thus far in 2026, six studies have compared the relative efficacy and safety of ocrelizumab and rituximab. Read More

Click here to complete the quick poll on PIRA.
Once you submit your responses, you will be able to view all of your colleagues’ responses.

SPECIAL REPORT

Effect of HE DMTs on PIRA
Anti-CD20 therapy and PIRA
Future use of PIRA

Progression independent of relapse activity (PIRA) has emerged as a means of identifying neurodegenerative processes that can occur at the earliest stages of the MS disease process and which contribute to disability accrual even when there is no evidence of disease activity. PIRA is generally defined as confirmed disability progression (CDP) during a relapse-free period (e.g. >30 days before and >90 days after relapse). Unfortunately, over 300 permutations of this definition have been described (Muller et al. JAMA Neurol 2025;82:614-625), which has made it difficult to compare the prevalence of PIRA and the impact of treatments across studies. Read More